Loading…
Tenderkart now works inside Claude and ChatGPT: search and analyse tenders right from your chat
Loading…
Tender ID
Eligibility, documents, scope and key termsEligibility, required documents, scope of work and key terms of this tender, in one click.
| # | Company | Rank | Status |
|---|---|---|---|
| 1 | NAAccepted-Finance | NA | Accepted-Finance As per annexure |
| 2 | NAAccepted-Finance | NA | Accepted-Finance As per annexure |
| 3 | Rejected-Technical 216 B DDA LIG FLATS JHILMIL COLONY SHAHDARA SHAHDARA EAST DELHI DELHI 110095 | SHAHDARA | DELHI | 110095 | - | Rejected-Technical As per annexure. |
| 4 | Rejected-Technical | - | Rejected-Technical As per annexure. |
Tender Value
Refer Docs
Closing Date
28 Oct 2022, 5:00 pmClosed
Eligibility, documents, scope and key termsEligibility, required documents, scope of work and key terms of this tender, in one click.
MD, OSMCL
OSMCL, Bhubaneswar
Re Tender for Procurement Of Diagnostic Services From Prospective Diagnostic Centres Through Empanelment To Conduct Molecular Pathology Tests Of Samples Collected At Various Government Healthcare Facilities
2022_OSMCL_81541_1
OSMCL/2022-23/MOLECULAR/13
National Competitive Bid
Miscellaneous Services
Empanelment
90 days
OSMCL, Bhubaneswar
Please refer Tender documents.
3 documents required · 3 mandatory
₹5,600
E E, RW division, Baripada
Exempted
TENDER HALL, OSMCL, BHUBANESWAR
23 Dec 2022
17 Sept 2022
31 Oct 2022
17 Sept 2022
28 Oct 2022
26 Sept 2022
21 Sept 2022
AML Panel
PML-RARA : t( 15;17 )
PML-RARA : t( 15;17 ) Variants
Inversion (16)
AML-ETO: t(8;21)
MLL rearrangement; 11q23
AML mutation Pannel (FLT3, NPM1, CEBPA, TP53, IDH, TET2)
MDS Panel
B-ALL Panel
T-ALL Panel
BCR/ABL Ph: t (9; 22)
BCR/ABL (Ph) Duplication, Trisomy 8, Trisomy 21, TP53 deletion
ABL kinase domain mutation ( TKI resistance )
RT-PCR BCR-ABL ( P190, P210)
RQ-PCR BCR-ABL (P210)
JAK 2 mutation
CLL Panel by FISH
IGVH mutation
Lymphoma Panel
IgH/BCL2 : t (14;18)
BCL6 rearrangement
MyC/IgH: t(8;14)
CCND1/IgH : t(11;14)
IgH/BCL3 : t (14;19)
Plasma cell neoplasms (MM) MM Panel by FISH; del 13, del17p13, t(4;14),t(11:14),t(14;16),t(14;20), 1p deletion, 1q21 gain/amplification
RQ-PCR based assay for MRD monitoring of Acute Leukemia
Her2Neu (FISH/DDISH)
BRCA 1, BRCA 2 mutation
PIK3CA mutation
KRAS, NRAS
Her 2 nuby FISH
PDGFR A mutation
Mutation in KIT
MET Exon-14 skipping mutation
Thyroid: BRAF, KRAS, NRAS, TERT
MGMT Promoter methylation
Interphase FISH for 1p,19q
IDH mutation
Medulloblastoma molecular Profilling
Neuroblastoma Interphase FISH for NMYC
BRCA1, BRCA2
HRR Panel
Endometrial carcinoma
Cervical carcinoma
High grade ESS t(10:17) (q22;p13)
High grade ESS t(x:22) (p11;q13)
Bladder cancer
Epitheloidhemangioendotheliomat(1:13) (p36;q25)
Alveolar soft part t(X:17) (p11;q25)
Myxoid Liposarcoma t(12:22)(q13:p11)
Clear cell sarcoma t(12:22) (q13;q12)
Clear cell sarcoma t(2:22) (q33;q12)
Synovial Sarcoma t(x:18)(p11;q11)
DFSP t(17:22) (p21;q13)
Extra renal Rhabdoid tumor: Inactivation of INI-1
PAX3-FOXO1: t( 2;13)
PAX7-FOXO1: t( 1;13)
RT-PCR for PAX-FKHR translocation
RT-PCR for EWS-FLI translocation
RT-PCR for EWS-ERG translocation
RT-PCR for EWS-WT1 translocation
Interphase FISH for EWSR1
Neuroblastoma
Familial carcinomas including BRCA, RET, VHL etc
Infectious diseases including TB
EBV DNA Detection
EBER in situ Hybridisation
RT-PCR for EBV analysis
Mycobacterium Tuberculosis detection on FFPE
Cervical cancer HPV
NGS NSCLC PANEL
GenX Diagnostics Private Limited
GenX Diagnostics Private Limited
stage.html
html • 0.04 MB
tech_eval.pdf
boq_comp_chart.xlsx
xlsx
fin_eval.pdf
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
html • 0.03 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .